An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes

References

• Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005 Oct 19; CD005533. Review
   Web of Science ®Google Scholar
• Durcharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006 Oct 18; CD003137. Review
   Google Scholar
• Masoli M, Weatherall M, Holt S, et al. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005;60:730-4
   PubMed Web of Science ®Google Scholar
• Stempel DA, O’Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002;109:433-9
   PubMed Web of Science ®Google Scholar
• O’Connor RD, Carranza Rosenzweig JR, Stanford RH, et al. Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of three commonly used controller regimens. Ann Allergy Asthma Immunol 2005;95:535-40
   PubMed Web of Science ®Google Scholar
• Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. National Heart, Lung, and Blood Institute, National Institutes of Health, National Heart, Lung, and Blood Institute. Available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm. Accessed June 17, 2008
   Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2007. Available at http://www.ginasthma.org. Accessed June 17, 2008
   Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26
   PubMed Web of Science ®Google Scholar
• Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7
   PubMed Web of Science ®Google Scholar
• Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005 Jan 15;330:117. Epub 2004 Dec 23
   PubMed Web of Science ®Google Scholar
• American Lung Association Epidemiology & Statistics Unit Research Program Services. Trends in Asthma Morbidity and Mortality. November 2007. Available at: www.lungusa.org. Accessed June 17, 2008
   Google Scholar
• Miniño AM, Heron MP, Smith BL. Deaths: preliminary data for 2004. Natl Vital Stat Rep 2006;54:1-49
   Google Scholar
• DiSantostefano RL, Davis KJ, Yancey S, et al. Ecologic analysis of asthma-related events and dispensing of inhaled corticosteroid- and salmeterol-containing products. Ann Allergy Asthma Immunol 2008;100:558-65
   PubMed Web of Science ®Google Scholar
• Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008;149:33-42
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92
   PubMed Web of Science ®Google Scholar
• Avorn J. In defense of pharmacoepidemiology – embracing the yin and yang of drug research. N Engl J Med 2007;357:2219-21
   PubMed Web of Science ®Google Scholar
• Benson K, Hartz A. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• SAS Institute, Inc., Cary, NC
   Google Scholar
• StataCorp, LP, College Station, TX
   Google Scholar
• Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta-2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma (review). Cochrane Database Syst Rev 2005 Oct 19; CD005535. Review
   Google Scholar
• Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000;105:1108-16
   PubMed Web of Science ®Google Scholar
• Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 µg and fluticasone propionate 250 µg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000;161:527-34
   PubMed Web of Science ®Google Scholar
• Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001;107:3-8
   PubMed Web of Science ®Google Scholar
• Ford JG, Meyer IH, Sternfels P, et al. Patterns and predictors of asthma-related emergency department use in Harlem. Chest 2001;120:1129-35
   PubMed Web of Science ®Google Scholar
• Griswold SK, Nordstrom CR, Clark S, et al. Asthma exacerbations in North American adults. Who are the “frequent fliers” in the emergency department? Chest 2005;127:1579-86
   PubMed Web of Science ®Google Scholar
• Miller MK, Lee JH, Blanc PD, et al. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Eur Respir J 2006;28:1145-55
   PubMed Web of Science ®Google Scholar
• Miller MK, Lee JH, Miller DP, et al. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med 2007;101:481-9
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2007;167:492-9
   PubMed Web of Science ®Google Scholar